Intravitreal Triamcinolone Acetonide in Eyes With Recurrent Postvitrectomy Diabetic Vitreous Hemorrhage - 19/08/11
Inquiries to June-Gone Kim, MD, Assistant Professor of Ophthalmology, Department of Ophthalmology, University of Ulsan, Asan Medical Center, #388-1, Poongnap-dong, Songpa-gu, Seoul, Korea, 138-040Résumé |
Purpose |
To evaluate the efficacy of intravitreal triamcinolone acetonide (IVT) for the management of recurrent post-vitrectomy diabetic vitreous hemorrhage (VH).
Design |
Interventional case series.
Methods |
Five eyes of five patients with recurrent postvitrectomy diabetic VH done more than three times where the common standard treatments has failed were administered 4 mg (0.1 ml) of triamcinolone acetonide ophthalmic suspension. The efficacy of IVT injection was assessed on day one; weeks one, two, and four; and months two and three.
Results |
The visual acuity (VA) at the time of IVT injection ranged from hand motion (HM) to counting fingers (CF). Of the five eyes, four eyes experienced clearing of VH on seven, four, one, and one week after IVT injection with visible triamcinolone precipitates with blood clot in the inferior aspect of fundus. Of these four eyes, two eyes had visual improvement with 20/50 and 20/200, whereas two eyes developed recurrent VH. VH was not cleared in one eye, which required surgical procedure.
Conclusions |
IVT injection may be beneficial for clearing recurrent post-vitrectomy VH, possibly by mechanical sedimentation of triamcinolone with retained blood clot.
Le texte complet de cet article est disponible en PDF.
Vol 142 - N° 3
P. 501-503 - septembre 2006 Retour au numéro
Article précédent
- Ocular Decompression Devices: Liquid Mercury Balloon vs the Tungsten Powder Balloon
- Steven Gayer, David Denham, Karim Alarakhia, Andres Bernal, Gabriel Cardenas, Robert Duncan, Jean-Marie Parel
- Third-Generation Optical Coherence Tomography Findings in Punctate Retinal Toxoplasmosis
- Juliana L. Oréfice, Rogério A. Costa, Wesley Campos, Daniela Calucci, Ingrid U. Scott, Fernando Oréfice
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?